- Company
- Organizations and people change
- by Eo, Yun-Ho Mar 3, 2023 05:57am
- The Korean branch of Gilead is facing the most significant transformation since its inception in Korea. Various changes such as the establishment of a new business unit are expected along with changes in the composition of the workforce, such as the resignation of executive director Jeong Yeon-shin, a key member of Gilead Sciences Korea al
- Company
- MFDS approves LG Chem’s P3T for new gout drug
- by Hwang, Jin-joon Mar 3, 2023 05:56am
- On the 28th, LG Chem announced that its global Phase III clinical trial protocol (EURELIA 2 Study) for ‘tigulixostat’ was approved by the Ministry of Food and Drug Safety. Tigulixostat is a new gout drug candidate being developed by LG Chem. The Phase III trial will enroll 2,600 gout patients with hyperuricemia around the globe. LG
- Company
- Corona drug competition system is imminent
- by Jung, Sae-Im Mar 3, 2023 05:55am
- As the COVID-19 pandemic shows signs of ending this year, pharmaceutical companies supplying related medicines are in the midst of preparing marketing and sales personnel to prepare for the end of the pandemic. According to the pharmaceutical industry on the 24th, Pfizer Korea is currently hiring large-scale new sales staff. The number of
- Company
- Sky Zoster ranked first in sales of shingles vaccine last yr
- by Kim, Jin-Gu Mar 2, 2023 05:53am
- SK Bioscience announced on the 28th, citing IMS data, a global market research institute, that its self-developed shingles vaccine Sky Zoster achieved the top share in sales in the domestic market last year. According to SK Bioscience, Sky Zoster's domestic market share last year reached 54% based on sales volume. Quarterly by quarter, 51
- Company
- Samsung Bioepis fiercely chases Celltrion in biosimilar mkt
- by Kim, Jin-Gu Mar 2, 2023 05:53am
- Samsung Bioepis has been rapidly chasing Celltrion in the domestic biosimilar business and expanding sales in the market. As of last year, domestic biosimilar sales of Samsung Bioepis and Celltrion were KRW 42.5 billion and KRW 69 billion, respectively. Samsung Bioepis’s sales more than tripled in one year, greatly narrowing the gap with
- Company
- Verquvo takes one step toward insurance coverage listing
- by Eo, Yun-Ho Mar 2, 2023 05:53am
- According to related industries, Bayer Korea's soluble guanylate cyclase (sGC) promoter Verquvo, which promotes the synthesis of intracellular cyclic monophosphate (cGMP), recently passed the HIRA. As a result, attention is focused on the future schedule of the Pharmaceutical Reimbursement Evaluation Committee. In December 2021, death due
- Company
- Daewoong botulinum toxin Nuceiva launched in Germany and Aus
- by Hwang, Jin-joon Mar 2, 2023 05:52am
- Daewoong Pharmaceutical announced on the 28th that its botulinum toxin 'Nuceiva' was officially launched in Germany and Austria through Evolus, a cosmetic indication partner in developed countries. Evolus, a partner for cosmetic indications in North America and the European Union, will be in charge of the distribution and marketing of Nuciva
- Company
- Jardiance vs Forxiga, competition in chronic kidney dz
- by Eo, Yun-Ho Feb 28, 2023 05:53am
- Competition outside the diabetes area for SGLT-2 inhibitors will further expand this year Following heart failure, this time it is kidney disease. Following AstraZeneca's Forxiga, Lilly and Boehringer Ingelheim's Jardiance also secured indications for chronic kidney disease, and competition is intensifying. In terms of speed, Forxiga is ahead
- Company
- Last year’s sales of Yuhan Leclaza were 16.1 billion won
- by Chon, Seung-Hyun Feb 28, 2023 05:52am
- Cumulative sales of 20 billion won in 1 year and 6 months after release. High growth prospects when promoted to first-line treatment. Yuhan Corporation's anti-cancer drug Leclaza is successfully settling in the domestic market. In the second year of its release, it posted sales of 16.1 billion won, breaking the record for annual sales of a new a
- Company
- Recordati Korean subsidiary was launched
- by Eo, Yun-Ho Feb 28, 2023 05:52am
- Italian pharmaceutical company Recordati Korean corporation was launched. Recordati Korea (Representative Lee Yeon-jae in Asia) announced on the 27th that it will officially launch its Korean branch and Asia-Pacific regional headquarters. The company is an Italian pharmaceutical company with a history of more than 90 years. Accordingly, the c
